A groundbreaking study published in the April 2025 issue of Oncotarget illuminates the complex immune dynamics within high-grade squamous intraepithelial lesions (HSILs) of the anogenital region, shedding light on the interplay between viral oncogenesis and immune evasion mechanisms. Researchers from the Instituto D’Or de Pesquisa e Ensino and Rede D’Or in Brazil examined the expression patterns of programmed death-ligand 1 (PD-L1) and forkhead box P3 (FOXP3), two pivotal immunoregulatory markers, within tissue samples from patients afflicted with HPV-related lesions. Their findings unmask how early immune alterations at the cellular level may dictate the malignant progression of these lesions, providing critical insights into potential intervention points before invasive cancer manifests.
Human papillomavirus (HPV) infection constitutes a major etiological factor in anogenital cancers, responsible for initiating persistent epithelial changes known as squamous intraepithelial lesions. Distinguishing between low-grade (LSIL) and high-grade lesions is clinically crucial, given the divergent outcomes—LSILs frequently resolve spontaneously, whereas HSILs have an increased propensity to progress toward invasive carcinoma. Yet, the immune milieu that determines these divergent paths remains poorly understood. This study targeted such immunological underpinnings by focusing on FOXP3+ regulatory T cells (Tregs) and PD-L1 expression, molecules intimately involved in immune modulation and tumor immune escape.
By analyzing tissues derived from 157 patients (comprising 95 males and 55 females) exhibiting either LSILs or HSILs across the anal, vulvar, and penile regions, the research team performed in situ immunohistochemical profiling to quantify FOXP3 and PD-L1 expression. notably, they found a pronounced enrichment of FOXP3+ Tregs in high-grade lesions compared to their low-grade counterparts. Tregs are known to suppress effector immune responses, thus potentially enabling HPV-infected cells to evade immune-mediated elimination. Parallel to these observations, PD-L1 expression—particularly marked by the SP142 and 22C3 antibody clones—was significantly elevated in inflammatory immune cells within HSILs, suggesting an active mechanism of immune checkpoint-mediated inhibition at the lesion site.
The overexpression of PD-L1 in high-grade lesions hints at a viral strategy to subvert host immune surveillance early in the infectious timeline. PD-L1 binds to PD-1 on cytotoxic T cells, downregulating their activity and encouraging an immunosuppressive microenvironment. This molecular handshake effectively puts brakes on the immune system’s tumor-fighting capacity, creating a sanctuary for HPV-infected epithelial cells to persist and potentially accumulate oncogenic mutations. The conjunction of high FOXP3+ Treg presence and PD-L1 upregulation delineates an immunosuppressive niche within HSILs that favors viral persistence and carcinogenic progression.
Moreover, the study’s rigorous statistical evaluations, including Poisson generalized linear modeling, underscored the significance of these molecular differences. The frequency of dense inflammatory cell infiltrates and elevated FOXP3+ counts in HSILs bore p-values of 0.04 and 0.02, respectively, while heightened PD-L1 expression achieved adjusted p-values below 0.01 for both clones tested. Such statistical robustness bolsters the premise that immune suppression is not an incidental phenomenon but a hallmark feature distinguishing progressive high-grade lesions from more benign low-grade forms.
Importantly, these immunological characteristics were discerned irrespective of HIV status, emphasizing that HPV-driven immune evasion mechanisms operate both in immunocompromised and immunocompetent hosts. While HIV-positive individuals generally demonstrated more extensive lesions, the presence of FOXP3 and PD-L1 was notable even among patients with intact immune systems. This universality stresses the intrinsic capacity of HPV to manipulate local immune responses, underlining the broad relevance of these findings for diverse patient populations.
The clinical implications of this work are substantial. Recognizing the co-expression of FOXP3 and PD-L1 as early predictors of lesion persistence and carcinogenic potential offers clinicians valuable biomarkers for tailoring surveillance strategies. Current screening paradigms rely heavily on histopathological grading, yet the addition of immunologic markers could refine risk stratification, ensuring that patients with high-risk lesions receive timely intervention while sparing those with transient infections from overtreatment.
From a therapeutic perspective, the data present compelling rationale for investigating immune checkpoint inhibitors and Treg-modulating agents in premalignant settings. Although checkpoint blockade therapies have revolutionized treatment for established cancers, their role in preventing progression from high-grade precursors remains unexplored. Targeting PD-L1-mediated pathways early may restore effective anti-viral immunity, potentially halting malignant transformation at its inception.
Fundamentally, this study enriches our understanding of the immunopathology underlying HPV-induced neoplasia. It highlights how viral oncogenesis co-opts host immune regulation, transforming what begins as a viral infection into a microenvironment conducive to malignant evolution. The delicate balance between immune activation and suppression is decisively tipped by HPV to favor persistence and progression, manifesting through increased PD-L1 expression and Treg infiltration as documented herein.
Though the research predominantly focuses on the anogenital region, its broader lessons may extend to other HPV-related malignancies, such as oropharyngeal cancers, where immune escape similarly underpins disease advancement. It sets a precedent for integrated immunopathologic analyses in early lesions, moving beyond morphological assessment to molecular dissection that informs both prognosis and therapeutic innovation.
Furthermore, the open-access publication of these findings enables wide dissemination within the oncology and virology communities, fostering an interdisciplinary discourse critical for translating these insights into clinical practice. Such transparency aligns with the evolving trend toward harnessing collective expertise and collaborative research to tackle complex viral oncogenesis effectively.
Looking ahead, future investigations will need to explore the dynamic interplay between additional immune checkpoints, effector T cell subtypes, and the tumor microenvironment within HPV-driven lesions. Decoding these relationships will be pivotal in designing next-generation immunotherapies and preventive strategies aimed at intercepting cancer development before it can take root.
In sum, this seminal work by Carneiro et al. not only advances the scientific narrative surrounding HPV-mediated carcinogenesis but also charts a promising course toward personalized immunological interventions in the prevention and management of anogenital cancers. The dual expression of PD-L1 and FOXP3 within HSILs emerges as a critical biomarker axis signaling immune escape, lesion persistence, and potential malignant progression—opening avenues for transformative advances in oncology and public health.
Subject of Research: People
Article Title: PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region
News Publication Date: 24-Apr-2025
Web References:
Image Credits: Copyright: © 2025 Carneiro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Keywords: cancer, HPV, high-grade intraepithelial lesion, immune evasion, PD-L1, FOXP3
